Human eye BTXExpert

The History of BTX in Ophthalmology

Medically reviewed and updated for accuracy by Dr Meg Minasian, MBBS, FRCOphth. (Last reviewed: May 2026)

The History of BTX in Ophthalmology

Botulinum toxin is now widely recognised in both medical and aesthetic practice. However, many people are unaware that modern therapeutic BTX treatment has important origins within ophthalmology.

Early clinical research involving eye movement disorders and periocular muscle conditions played a major role in the development of modern botulinum toxin medicine.

Understanding this history helps place contemporary aesthetic treatment within a much broader scientific and medical context.

Early Interest in Muscle Relaxation

Botulinum toxin works by temporarily reducing signalling between nerves and muscles.

Researchers became interested in whether this mechanism could be used therapeutically in conditions involving abnormal muscle contraction and movement.

The highly specialised muscles controlling eye movement provided an important early area for investigation during the 1970s.

Strabismus and Eye Muscle Disorders

One of the earliest major therapeutic applications involved strabismus, a condition involving imbalance of the extraocular muscles controlling eye alignment.

Because eye position depends on extremely precise muscular coordination, researchers explored whether temporary weakening of selected eye muscles could help influence ocular alignment.

This work helped establish the foundations of therapeutic BTX treatment during the late 1970s and early 1980s.

Dr Alan Scott and Early Research

During the 1970s and early 1980s, ophthalmologist Dr Alan Scott played a central role in pioneering early therapeutic botulinum toxin research.

Working in the field of eye movement disorders, he investigated the use of botulinum toxin in extraocular muscles as a non-surgical approach in selected cases of strabismus.

This research later contributed to the broader medical development of botulinum toxin therapy.

Dr Scott’s work is widely regarded as historically important in the evolution of therapeutic BTX medicine.

In 1989, botulinum toxin type A received early regulatory approval in the United States for conditions including strabismus and blepharospasm.

Expansion Beyond Strabismus

Throughout the 1980s and 1990s, clinical use expanded into additional ophthalmic and neurological conditions involving abnormal muscle activity.

These included:

This broader clinical experience contributed to growing understanding of:

  • muscle physiology
  • nerve signalling
  • injection techniques
  • functional anatomy.

From Ophthalmology to Broader Medicine

By the late 1990s and early 2000s, BTX treatment had expanded significantly into:

  • neurology
  • rehabilitation medicine
  • pain management
  • urology
  • dermatology
  • eventually aesthetic medicine.

Over time, public awareness became increasingly focused on cosmetic treatment, although the medical and neurological foundations remained highly important.

Why Ophthalmology Was So Important

The periocular region involves highly specialised anatomy responsible for:

  • blinking
  • eye protection
  • tear film maintenance
  • binocular coordination
  • visual function.

Working within this anatomically precise region required detailed understanding of:

  • muscle balance
  • nerve function
  • movement dynamics
  • functional anatomy.

These principles later influenced broader BTX treatment approaches across multiple specialties.

The Evolution of Modern BTX Medicine

Today, botulinum toxin is used across a wide range of medical and aesthetic indications.

However, many modern applications trace part of their development back to early ophthalmic and neuro-ophthalmic research involving eye muscle disorders.

Understanding this historical pathway highlights how modern BTX treatment evolved from functional neurological and ophthalmological medicine rather than purely cosmetic origins.

Why This History Matters

Public discussion surrounding BTX often focuses primarily on aesthetics.

The ophthalmological history of botulinum toxin helps demonstrate:

  • the medical origins of treatment
  • the importance of anatomy and function
  • the role of neuroscience
  • the broader therapeutic significance of BTX within modern medicine.

This historical perspective remains important when discussing both the possibilities and limitations of botulinum toxin treatment today.

Frequently Asked Questions

Was BTX originally developed for cosmetic use?

No. Early therapeutic development involved medical applications, particularly within ophthalmology and eye movement disorders.

Who was Dr Alan Scott?

Dr Alan Scott was an ophthalmologist who played a major role in pioneering early therapeutic botulinum toxin research.

Why was ophthalmology important in BTX history?

Eye movement disorders provided an important early area for studying controlled muscle relaxation using botulinum toxin.

Did strabismus research contribute to modern BTX medicine?

Yes. Early work involving strabismus helped shape broader therapeutic BTX development.

Is BTX still important in ophthalmology treatments today?

Yes. Botulinum toxin continues to play important roles in ophthalmology, neuro-ophthalmology and periocular movement disorders.

Back to top ↑

Related Articles

– BTX for Strabismus
– BTX Around The Eyes Explained
– BTX and Blinking Explained
– BTX for Blepharospasm
– BTX for Hemifacial Spasm
– BTX and Facial Anatomy Explained

Back to top ↑

Further Reading & References

Medical Disclaimer

The information provided on BTXExpert is intended for educational purposes only and should not be considered medical advice. Individuals should seek personalised advice from an appropriately qualified healthcare professional regarding diagnosis, treatment suitability, risks and alternatives.